The Management of Diabetic Neuropathy in CKD

American Journal of Kidney Diseases

Volumn 55, Issue 2, 2010, Pages 365-385

  Pop Busui, Rodica ^a   Roberts, Laurel ^a   Pennathur, Subramaniam ^a   Kretzler, Mathias ^a   Brosius, Frank C ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

autonomic neuropathy; chronic kidney disease; Diabetes mellitus; management; peripheral neuropathy

Indexed keywords

AMITRIPTYLINE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPSAICIN; CARBAMAZEPINE; CARVEDILOL; DESIPRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; ENALAPRIL; EPROSARTAN; GABAPENTIN; IMIPRAMINE; LOSARTAN; MIDODRINE; NORTRIPTYLINE; OPIATE; OXYCODONE; PAROXETINE; PHENYTOIN; PREGABALIN; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TELMISARTAN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADD ON THERAPY; ANALGESIA; ANEMIA; ANKLE EDEMA; ANXIETY; APPLICATION SITE BURNING; ARTICLE; ATAXIA; AUTONOMIC NEUROPATHY; BEDTIME DOSAGE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE; CARDIAC AUTONOMIC NEUROPATHY; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS DISORDER; CONSTIPATION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DYSPEPSIA; EUPHORIA; EXERCISE TOLERANCE; FOOT CARE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DISEASE; HEART INDEX; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE VARIABILITY; HEART SCINTISCANNING; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; IMMUNE DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LEG AMPUTATION; MOLECULAR MECHANICS; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCLE EXCITATION; MYOCLONUS; NAUSEA; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PATHOGENESIS; PERIPHERAL NEUROPATHY; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SYMPATHETIC TONE; TACHYCARDIA; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; URINE RETENTION; WEIGHT GAIN;

AUTONOMIC NERVOUS SYSTEM DISEASES; CHRONIC DISEASE; DIABETIC NEUROPATHIES; HEART DISEASES; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 74449084894     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.10.050     Document Type: Article

References (164)

1. Kamal-Bahl S.J., Pantely S., and Pyenson B. Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease [abstract]. Prev Chronic Dis 3 3 (2006) 83A. http://www.cdc.gov/pcd/issues/2006/jul/05_0210.htm Accessed September 1, 2009
2. Fernando D.J., Hutchison A., Veves A., Gokal R., and Boulton A.J. Risk factors for non-ischaemic foot ulceration in diabetic nephropathy. Diabet Med 8 3 (1991) 223-225
3. Navarro X., Kennedy W.R., and Sutherland D.E. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia 34 suppl 1 (1991) S108-S112
4. Rathmann W., Ziegler D., Jahnke M., Haastert B., and Gries F.A. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 10 9 (1993) 820-824
5. Sampson M.J., Wilson S., Karagiannis P., Edmonds M., and Watkins P.J. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med 75 278 (1990) 635-646
6. Manjunath G., Levey A.S., and Sarnak M.J. How can the cardiac death rate be reduced in dialysis patients?. Semin Dial 15 1 (2002) 18-20
7. Locatelli F., Marcelli D., and Conte F. Dialysis patient outcomes in Europe vs the USA. Why do Europeans live longer?. Nephrol Dial Transplant 12 9 (1997) 1816-1819
8. Locatelli F., Marcelli D., Conte F., et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 12 11 (2001) 2411-2417
9. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2006), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
10. Ranpuria R., Hall M., Chan C.T., and Unruh M. Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrol Dial Transplant 23 2 (2008) 444-449
11. Hathaway D.K., Cashion A.K., Milstead E.J., et al. Autonomic dysregulation in patients awaiting kidney transplantation. Am J Kidney Dis 32 2 (1998) 221-229
12. Zander E., Schulz B., Heinke P., Grimmberger E., Zander G., and Gottschling H.D. Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy. Diabetes Care 12 4 (1989) 259-264
13. Chang M.H., and Chou K.J. The role of autonomic neuropathy in the genesis of intradialytic hypotension. Am J Nephrol 21 5 (2001) 357-361
14. Laaksonen S., Voipio-Pulkki L., Erkinjuntti M., Asola M., and Falck B. Does dialysis therapy improve autonomic and peripheral nervous system abnormalities in chronic uraemia?. J Intern Med 248 1 (2000) 21-26
15. Spallone V., Mazzaferro S., Tomei E., et al. Autonomic neuropathy and secondary hyperparathyroidism in uraemia. Nephrol Dial Transplant 5 suppl 1 (1990) S128-S130
16. Johansson M., Gao S.A., Friberg P., et al. Reduced baroreflex effectiveness index in hypertensive patients with chronic renal failure. Am J Hypertens 18 7 (2005) 995-1000 discussion 1016
17. Brouns R., and De Deyn P.P. Neurological complications in renal failure: a review. Clin Neurol Neurosurg 107 1 (2004) 1-16
18. Innis J. Pain assessment and management for a dialysis patient with diabetic peripheral neuropathy. CANNT J 16 2 (2006) 12-17 20-16; quiz 18-19, 27-18
19. Stella P., Ellis D., Maser R.E., and Orchard T.J. Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes. Incidence and predictors. J Diabetes Complications 14 1 (2000) 1-6
20. Witte D.R., Tesfaye S., Chaturvedi N., Eaton S.E., Kempler P., and Fuller J.H. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 48 1 (2005) 164-171
21. + pump dysfunction in diabetic neuropathy. Brain 131 pt 5 (2008) 1209-1216
22. Greene D.A., and Lattimer S.A. Impaired energy utilization and Na-K-ATPase in diabetic peripheral nerve. Am J Physiol 246 (1984) E311-E318
23. Edwards J.L., Vincent A.M., Cheng H.T., and Feldman E.L. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 120 1 (2008) 1-34
24. Pop-Busui R., Sima A., and Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 22 4 (2006) 257-273
25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 6865 (2001) 813-820 13
26. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 6 (2005) 1615-1625
27. Massry S.G. Parathyroid hormone: a uremic toxin. Adv Exp Med Biol 223 (1987) 1-17
28. Slatopolsky E., Martin K., and Hruska K. Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol 239 1 (1980) F1-F12
29. Vanholder R., De Smet R., Hsu C., Vogeleere P., and Ringoir S. Uremic toxicity: the middle molecule hypothesis revisited. Semin Nephrol 14 3 (1994) 205-218
30. Kaji R., and Sumner A.J. Ouabain reverses conduction disturbances in single demyelinated nerve fibers. Neurology 39 10 (1989) 1364-1368
31. Krishnan A.V., Phoon R.K., Pussell B.A., Charlesworth J.A., Bostock H., and Kiernan M.C. Altered motor nerve excitability in end-stage kidney disease. Brain 128 pt 9 (2005) 2164-2174
32. Krishnan A.V., Phoon R.K., Pussell B.A., Charlesworth J.A., Bostock H., and Kiernan M.C. Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain 129 pt 6 (2006) 1585-1592
33. Craner M.J., Lo A.C., Black J.A., and Waxman S.G. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 126 pt 7 (2003) 1552-1561
34. Kiernan M.C., Walters R.J., Andersen K.V., Taube D., Murray N.M., and Bostock H. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 125 pt 6 (2002) 1366-1378
35. Krishnan A.V., and Kiernan M.C. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 35 3 (2007) 273-290
36. Converse Jr. R.L., Jacobsen T.N., Toto R.D., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327 27 (1992) 1912-1918
37. Siddiqi L., Joles J.A., Grassi G., and Blankestijn P.J. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system?. J Hypertens 27 7 (2009) 1341-1349
38. Axelrod S., Lishner M., Oz O., Bernheim J., and Ravid M. Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic nervous control in chronic renal failure. Nephron 45 3 (1987) 202-206
39. Campese V.M., Romoff M.S., Levitan D., Lane K., and Massry S.G. Mechanisms of autonomic nervous system dysfunction in uremia. Kidney Int 20 2 (1981) 246-253
40. Paulson D.J., and Light K.E. Elevation of serum and ventricular norepinephrine content in the diabetic rat. Res Commun Chem Pathol Pharmacol 33 3 (1981) 559-562
41. Givertz M.M., Sawyer D.B., and Colucci W.S. Antioxidants and myocardial contractility: illuminating the "dark side" of beta-adrenergic receptor activation?. Circulation 103 6 (2001) 782-783
42. Felten S.Y., Peterson R.G., Shea P.A., Besch Jr. H.R., and Felten D.L. Effects of streptozotocin diabetes on the noradrenergic innervation of the rat heart: a longitudinal histofluorescence and neurochemical study. Brain Res Bull 8 6 (1982) 593-607
43. Scacco S., Vergari R., Scarpulla R.C., et al. cAMP-dependent phosphorylation of the nuclear encoded 18-kDa (IP) subunit of respiratory complex I and activation of the complex in serum-starved mouse fibroblast cultures. J Biol Chem 275 23 (2000) 17578-17582
44. Iwai-Kanai E., Hasegawa K., Araki M., Kakita T., Morimoto T., and Sasayama S. Alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 100 3 (1999) 305-311
45. Communal C., Singh K., Pimentel D.R., and Colucci W.S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98 13 (1998) 1329-1334
46. Colberg S.R., Swain D.P., and Vinik A.I. Use of heart rate reserve and rating of perceived exertion to prescribe exercise intensity in diabetic autonomic neuropathy. Diabetes Care 26 4 (2003) 986-990
47. Giordano M., Manzella D., Paolisso G., Caliendo A., Varricchio M., and Giordano C. Differences in heart rate variability parameters during the post-dialytic period in type II diabetic and non-diabetic ESRD patients. Nephrol Dial Transplant 16 3 (2001) 566-573
48. Ewing D.J., Campbell I.W., and Clarke B.F. The natural history of diabetic autonomic neuropathy. Q J Med 49 193 (1980) 95-108
49. Ewing D.J., and Clarke B.F. Diagnosis and management of diabetic autonomic neuropathy. Br Med J 285 6346 (1982) 916-918
50. Ewing D.J., and Clarke B.F. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 9 6 (1986) 648-665
51. Vinik A.I., and Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 115 3 (2007) 387-397
52. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 46 5 (1996) 1470
53. Kersh E.S., Kronfield S.J., Unger A., Popper R.W., Cantor S., and Cohn K. Autonomic insufficiency in uremia as a cause of hemodialysis-induced hypotension. N Engl J Med 290 12 (1974) 650-653
54. Sato M., Horigome I., Chiba S., et al. Autonomic insufficiency as a factor contributing to dialysis-induced hypotension. Nephrol Dial Transplant 16 8 (2001) 1657-1662
55. Ligtenberg G., Blankestijn P.J., Boomsma F., and Koomans H.A. No change in automatic function tests during uncomplicated haemodialysis. Nephrol Dial Transplant 11 4 (1996) 651-656
56. Di Carli M.F., Bianco-Batlles D., Landa M.E., et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 100 8 (1999) 813-819
57. Di Carli M.F., Tobes M.C., Mangner T., et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 336 17 (1997) 1208-1215
58. Stevens M.J., Dayanikli F., Raffel D.M., et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol 31 7 (1998) 1575-1584
59. Nitenberg A., Valensi P., Sachs R., Dali M., Aptecar E., and Attali J.R. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42 7 (1993) 1017-1025
60. Nitenberg A., Antony I., and Foult J.M. [Coronary vasoconstriction induced by acetylcholine in young smokers with normal angiographic coronary vessels]. Arch Mal Coeur Vaiss 86 8 (1993) 1133-1136
61. Langer A., Freeman M.R., Josse R.G., and Armstrong P.W. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 25 3 (1995) 610-618
62. Schwartz P.J., Randall W.C., Anderson E.A., et al. Sudden cardiac death. Nonpharmacologic interventions. Circulation 76 1 pt 2 (1987) I215-I219
63. Willich S.N., Maclure M., Mittleman M., Arntz H.R., and Muller J.E. Sudden cardiac death. Support for a role of triggering in causation. Circulation 87 5 (1993) 1442-1450
64. Lown B., and Verrier R.L. Neural activity and ventricular fibrillation. N Engl J Med 294 21 (1976) 1165-1170
65. Maser R.E., Mitchell B.D., Vinik A.I., and Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 26 6 (2003) 1895-1901
66. Brown D.W., Giles W.H., and Croft J.B. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 140 6 (2000) 848-856
67. Levy D., Anderson K.M., Savage D.D., Balkus S.A., Kannel W.B., and Castelli W.P. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 60 7 (1987) 560-565
68. Nishimura M., Hashimoto T., Kobayashi H., et al. Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients. Nephrol Dial Transplant 19 10 (2004) 2532-2538
69. Low P.A., Denq J.C., Opfer-Gehrking T.L., Dyck P.J., O'Brien P.C., and Slezak J.M. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve 20 12 (1997) 1561-1568
70. Gelber D.A., Pfeifer M., Dawson B., and Schumer M. Cardiovascular autonomic nervous system tests: determination of normative values and effect of confounding variables. J Auton Nerv Syst 62 1-2 (1997) 40-44
71. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93 5 (1996) 1043-1065
72. Boulton A.J., Vinik A.I., Arezzo J.C., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28 4 (2005) 956-962
73. Allman K.C., Wieland D.M., Muzik O., Degrado T.R., Wolfe Jr. E.R., and Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol 22 2 (1993) 368-375
74. Stevens M.J., Raffel D.M., Allman K.C., et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 98 10 (1998) 961-968
75. Stevens M.J., Raffel D.M., Allman K.C., Schwaiger M., and Wieland D.M. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 48 1 (1999) 92-101
76. Kreiner G., Wolzt M., Fasching P., et al. Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 44 5 (1995) 543-549
77. Schnell O., Kirsch C.M., Stemplinger J., Haslbeck M., and Standl E. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia 38 11 (1995) 1345-1352
78. 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes 45 6 (1996) 801-805
79. Shimabukuro M., Chibana T., Yoshida H., Nagamine F., Komiya I., and Takasu N. Increased QT dispersion and cardiac adrenergic dysinnervation in diabetic patients with autonomic neuropathy. Am J Cardiol 78 9 (1996) 1057-1059
80. Turpeinen A.K., Vanninen E., Kuikka J.T., and Uusitupa M.I. Demonstration of regional sympathetic denervation of the heart in diabetes. Comparison between patients with NIDDM and IDDM. Diabetes Care 19 10 (1996) 1083-1090
81. Pop-Busui R., Kirkwood I., Schmid H., et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 44 12 (2004) 2368-2374
82. DeGrado T.R., Hutchins G.D., Toorongian S.A., Wieland D.M., and Schwaiger M. Myocardial kinetics of carbon-11-meta-hydroxyephedrine: retention mechanisms and effects of norepinephrine. J Nucl Med 34 8 (1993) 1287-1293
83. Schwaiger M., Hutchins G.D., Kalff V., et al. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest 87 5 (1991) 1681-1690
84. Ungerer M., Hartmann F., Karoglan M., et al. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation 97 2 (1998) 174-180
85. Hamner J.W., and Taylor J.A. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. J Appl Physiol 91 3 (2001) 1199-1206
86. Foster A.V., Snowden S., Grenfell A., Watkins P.J., and Edmonds M.E. Reduction of gangrene and amputations in diabetic renal transplant patients: the role of a special foot clinic. Diabet Med 12 7 (1995) 632-635
87. Eggers P.W., Gohdes D., and Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 56 4 (1999) 1524-1533
88. Combe C., Albert J.M., Bragg-Gresham J.L., et al. The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 54 4 (2009) 680-692
89. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. American Diabetes Association. Muscle Nerve 11 7 (1988) 661-667
90. Boulton A.J., Malik R.A., Arezzo J.C., and Sosenko J.M. Diabetic somatic neuropathies. Diabetes Care 27 6 (2004) 1458-1486
91. Adriaensen H., Plaghki L., Mathieu C., Joffroy A., and Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain-clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. Diabetes Metab Res Rev 21 3 (2005) 231-240
92. DCCT and UKPDS Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 (1993) 977-986
93. DCCT and UKPDS Study Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 38 6 (1995) 869-880
94. DCCT and UKPDS Study Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 41 4 (1998) 416-423
95. Tesfaye S., Stevens L.K., Stephenson J.M., et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 39 11 (1996) 1377-1384
96. Tesfaye S., Chaturvedi N., Eaton S.E., et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 352 4 (2005) 341-350
97. DCCT and UKPDS Study Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 19 (2002) 2563-2569
98. DCCT/EDIC Writing Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 290 16 (2003) 2159-2167
99. Pop-Busui R., Evans G., Gerstein H.C., et al. Cardiac autonomic dysfunction predicts cardiovascular mortality in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes suppl 1 (2009) 58:A63
100. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28 2 (1995) 103-117
101. DCCT and UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 837-853
102. DCCT and UKPDS Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 9131 (1998) 854-865
103. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 2 (2009) 129-139
104. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 5 (2003) 383-393
105. Ondocin P.T., and Narsipur S.S. Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis. Nephrology (Carlton) 11 6 (2006) 497-501
106. Weinbergova O., Metelka R., Vymetal J., Konecny K., and Kosatikova Z. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 148 1 (2004) 69-73
107. Tamura K., Tsuji H., Nishiue T., Yajima I., Higashi T., and Iwasaka T. Determinants of heart rate variability in chronic hemodialysis patients. Am J Kidney Dis 31 4 (1998) 602-606
108. Ligtenberg G., Blankestijn P.J., Oey P.L., et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340 17 (1999) 1321-1328
109. Neumann J., Ligtenberg G., Klein I.H., et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 49 3 (2007) 506-510
110. Pun P.H., Lehrich R.W., Smith S.R., and Middleton J.P. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2 3 (2007) 491-500
111. Cice G., Ferrara L., D'Andrea A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41 9 (2003) 1438-1444
112. Nakao K., Makino H., Morita S., et al. Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study. Nephron Clin Pract 113 3 (2009) c132-c139
113. Foley R.N., Herzog C.A., and Collins A.J. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62 5 (2002) 1784-1790
114. Stojcheva-Taneva O.O., and Polenakovic M.H. Autonomic neuropathy in hemodialysis patients treated with recombinant human erythropoietin. Int J Artif Organs 19 10 (1996) 574-577
115. Bakris G.L., Hart P., and Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 70 11 (2006) 1905-1913
116. Ebbehoj E., Poulsen P.L., Hansen K.W., Knudsen S.T., Molgaard H., and Mogensen C.E. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia 45 7 (2002) 965-975
117. Kamalesh M., Subramanian U., Sawada S., Eckert G., Temkit M., and Tierney W. Decreased survival in diabetic patients with heart failure due to systolic dysfunction. Eur J Heart Fail 8 4 (2006) 404-408
118. Tory K., Horvath E., Suveges Z., et al. Effect of propranolol on heart rate variability in patients with end-stage renal disease: a double-blind, placebo-controlled, randomized crossover pilot trial. Clin Nephrol 61 5 (2004) 316-323
119. Bristow M.R. What type of beta-blocker should be used to treat chronic heart failure?. Circulation 102 5 (2000) 484-486
120. Orth S.R., Amann K., Strojek K., and Ritz E. Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant 16 suppl 1 (2001) S67-S69
121. Paoletti E., Specchia C., Di Maio G., et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 19 7 (2004) 1829-1834
122. Bosman D.R., Winkler A.S., Marsden J.T., Macdougall I.C., and Watkins P.J. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24 3 (2001) 495-499
123. Hoeldtke R.D., and Streeten D.H. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 329 9 (1993) 611-615
124. Winkler A.S., Marsden J., Chaudhuri K.R., Hambley H., and Watkins P.J. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med 16 10 (1999) 813-819
125. Prakash S., Garg A.X., Heidenheim A.P., and House A.A. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. Nephrol Dial Transplant 19 10 (2004) 2553-2558
126. Rubinstein S., Haimov M., and Ross M.J. Midodrine-induced vascular ischemia in a hemodialysis patient: a case report and literature review. Ren Fail 30 8 (2008) 808-812
127. Yalcin A.U., Kudaiberdieva G., Sahin G., et al. Effect of sertraline hydrochloride on cardiac autonomic dysfunction in patients with hemodialysis-induced hypotension. Nephron Physiol 93 1 (2003) P21-P28
128. Agarwal A., Anand I.S., Sakhuja V., and Chugh K.S. Effect of dialysis and renal transplantation on autonomic dysfunction in chronic renal failure. Kidney Int 40 3 (1991) 489-495
129. Allon M., Rodriguez M., and Llach F. Insulin in the acute renal adaptation to dietary phosphate restriction in the rat. Kidney Int 37 1 (1990) 14-20
130. Rubinger D., Revis N., Pollak A., Luria M.H., and Sapoznikov D. Predictors of haemodynamic instability and heart rate variability during haemodialysis. Nephrol Dial Transplant 19 8 (2004) 2053-2060
131. Tong Y.Q., and Hou H.M. Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. Am J Nephrol 27 1 (2007) 63-69
132. Dursun B., Demircioglu F., Varan H.I., et al. Effects of different dialysis modalities on cardiac autonomic dysfunctions in end-stage renal disease patients: one year prospective study. Ren Fail 26 1 (2004) 35-38
133. Rubinger D., Backenroth R., Pollak A., and Sapoznikov D. Blood pressure and heart rate variability in patients on conventional or sodium-profiling hemodialysis. Ren Fail 30 3 (2008) 277-286
134. Max M.B., Culnane M., Schafer S.C., et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 37 4 (1987) 589-596
135. Max M.B., Lynch S.A., Muir J., Shoaf S.E., Smoller B., and Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326 19 (1992) 1250-1256
136. Sindrup S.H., Gram L.F., Brosen K., Eshoj O., and Mogensen E.F. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42 2 (1990) 135-144
137. Goldstein D.J., Lu Y., Detke M.J., Lee T.C., and Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 1-2 (2005) 109-118
138. Raskin J., Wang F., Pritchett Y.L., and Goldstein D.J. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 7 5 (2006) 373-385
139. Wernicke J.F., Pritchett Y.L., D'Souza D.N., et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67 8 (2006) 1411-1420
140. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 21 (1998) 1831-1836
141. Rosenstock J., Tuchman M., LaMoreaux L., and Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110 3 (2004) 628-638
142. Freynhagen R., Strojek K., Griesing T., Whalen E., and Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 3 (2005) 254-263
143. Richter R.W., Portenoy R., Sharma U., Lamoreaux L., Bockbrader H., and Knapp L.E. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6 4 (2005) 253-260
144. Harati Y., Gooch C., Swenson M., et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50 6 (1998) 1842-1846
145. Finnerup N.B., Otto M., McQuay H.J., Jensen T.S., and Sindrup S.H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118 3 (2005) 289-305
146. Jensen T.S., Madsen C.S., and Finnerup N.B. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 22 5 (2009) 467-474
147. Barrett A.M., Lucero M.A., Le T., Robinson R.L., Dworkin R.H., and Chappell A.S. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 8 suppl 2 (2007) S50-S62
148. Moore R.A., Straube S., Wiffen P.J., Derry S., and McQuay H.J. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 3 (2009) CD007076
149. Randinitis E.J., Posvar E.L., Alvey C.W., Sedman A.J., Cook J.A., and Bockbrader H.N. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 43 3 (2003) 277-283
150. Backonja M., and Glanzman R.L. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 25 1 (2003) 81-104
151. Wong M.O., Eldon M.A., Keane W.F., et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 35 6 (1995) 622-626
152. Zhang C., Glenn D.G., Bell W.L., and O'Donovan C.A. Gabapentin-induced myoclonus in end-stage renal disease. Epilepsia 46 1 (2005) 156-158
153. Hung T.Y., Seow V.K., Chong C.F., Wang T.L., and Chen C.C. Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. Emerg Med J 25 3 (2008) 178-179
154. Jones H., Aguila E., and Farber H.W. Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis [letter]. Ann Intern Med 137 1 (2002) 74
155. Collins S.L., Moore R.A., McQuay H.J., and Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 20 6 (2000) 449-458
156. Jann M.W., and Slade J.H. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy 27 11 (2007) 1571-1587
157. Wiffen P., Collins S., McQuay H., Carroll D., Jadad A., and Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 3 (2005) CD001133
158. Sindrup S.H., Andersen G., Madsen C., Smith T., Brosen K., and Jensen T.S. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 83 1 (1999) 85-90
159. Watson C.P., Moulin D., Watt-Watson J., Gordon A., and Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105 1-2 (2003) 71-78
160. Gilron I., Bailey J.M., Tu D., Holden R.R., Weaver D.F., and Houlden R.L. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 13 (2005) 1324-1334
161. Gilron I., Bailey J.M., Tu D., Holden R.R., Jackson A.C., and Houlden R.L. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 374 9697 (2009) 1252-1261
162. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group. Diabetes Care 15 2 (1992) 159-165
163. Yuan R.Y., Sheu J.J., Yu J.M., et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 72 17 (2009) 1473-1478
164. Klassen A., Di Iorio B., Guastaferro P., Bahner U., Heidland A., and De Santo N. High-tone external muscle stimulation in end-stage renal disease: effects on symptomatic diabetic and uremic peripheral neuropathy. J Ren Nutr 18 1 (2008) 46-51